Altered expression of Notch1 in Alzheimer's disease.

Notch signaling is an evolutionarily conserved pathway that regulates cell-cell interactions through binding of Notch family receptors to their cognate ligands. Notch signaling has an essential role in vascular development and angiogenesis. Recent studies have reported that Notch may be implicated in Alzheimer's disease (AD) pathophysiology. We measured the levels of soluble Notch1 (sNotch1) in the plasma samples from 72 dementia patients (average age 75.1 y), 89 subjects with amnestic mild cognitive impairment (MCI) (average age 73.72 y), and 150 cognitively normal controls (average age 72.34 y). Plasma levels of sNotch1 were 25.27% lower in dementia patients as compared to healthy control subjects. However, the level of Notch1 protein was significantly increased in human brain microvascular endothelial cells (HBMECs) after amyloid-beta treatment. Also, Notch1 mRNA level was significantly increased in HBMECs and iPSC-derived neuronal cells from AD patient compared to normal control. These results indicate that altered expression of Notch1 might be associated with the risk of Alzheimer's disease.

Introduction

Alzheimer’s disease (AD) is a complex neurodegenerative syndrome caused by abnormal accumulation of biological products for decades. Recently, it has been reported that Notch signaling in cerebrovascular diseases is associated with angiogenesis and the functioning of the blood-brain barrier (BBB)[1]. Notch1 could mediate neurodegenerative progress including AD. Notch is involved in regulating proteolytic processing of amyloid precursor protein (APP) through cleavage by ADAM10/17 and γ-secretase[2, 3]. The membrane-bound Notch receptor is cleaved into a secreted Notch extracellular truncation domain (NEXT) and an activated Notch intracellular domain (NICD). NICD translocates into the nucleus and modulates the expression of several genes[4]. Notch signaling cascade is involved in various intracellular signaling processes including BBB functioning, cerebrovascular formation, and the development of tissue-specific cell types[5, 6]. In BBB, during the vessel formation process, vascular endothelial growth factor A (VEGFA) is the most potent mitogen acting on endothelial cells (ECs). VEGFA stimulates vasculogenesis through VEGF receptor 2 (VEGFR2)-induced activation of DLL4 and Notch1 signaling pathway[7]. A recent study showed that Notch and VEGF signaling mediates vasculogenesis and angiogenesis through regulation of VEGFR2 in BBB[8].

In the brain, Notch signaling plays an important role in the developmental processes, synaptic plasticity, and glial cell activation[9-11]. Notch might also be involved in the neural stem cell activation in response to exercise, learning, or injury. However, the mechanism of Notch signaling-mediated fine-tuning of neurogenesis is not fully understood. Recently, it has been reported that Notch1 protein expression is significantly increased in the brain of patients with AD and Notch1 is deposited in Aβ1–42 positive plaques[12]. Plasma Notch1 and tumor necrosis factor-α converting enzyme (TACE) levels were significantly higher in the abdominal aortic aneurysm (AAA) postulating that the Notch1 signaling in macrophages plays an important role in AAA development and progression[13]. However, the plasma level of Notch1 has never been explored in AD. The level of full-length and truncated Notch1 in the cerebrospinal fluid (CSF) is reduced in AD patients suggesting its accumulation in the brain parenchyma[12]. These studies indicate that imbalance of Notch1 signaling might be implicated in AD. In our previous study, we examined the plasma levels of soluble VEGFR2 (sVEGFR2) are significantly decreased in AD patients[8]. We found that that the NOTCH1 mRNA level was significantly increased in human umbilical vein endothelial cells (HUVECs) after Aβ treatment. Overexpression of NICD significantly decreased the sVEGFR2 and VEGFR2 mRNA levels in HUVEC indicating that the altered VEGFR2 expression might be associated with AD[8].

In this study, we evaluated the changes in the plasma levels of Notch1 in AD and determined the role of Notch1 in regulating cerebrovasculogenesis in ECs. We demonstrated that the soluble Notch1 (sNotch1) levels are significantly decreased in the plasma of AD patients. These results highlight the importance of Notch1 as a potent biomarker in patients at risk for AD.

Materials and methods

Subjects

Control, subjects with mild cognitive impairment (MCI) and dementia subjects were selected from the population-based Ansan Geriatric (AGE) cohort established in 2002 to study the common geriatric diseases of elderly Koreans aged between 60–84 years. The sampling protocol and design of the AGE study have been previously described[14, 15] and the population of this study has referenced in our previous study[8, 16]. Cognitive functioning and memory impairments of the subjects were assessed using a Korean version of Consortium to Establish a Registry for Alzheimer's disease (CERAD-K) neuropsychological battery[17]. The basic structures of all measures in the original CERAD batteries were maintained in Korean translation. All participants were clinically evaluated according to published guidelines. All the dementia patient met the criteria as described in the Diagnostic and Statistical Manual of Mental Disorders, fourth edition[18] and the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS–ADRDA)[15]. MCI was diagnosed on the basis of the Mayo Clinic criteria [19] as described previously[20, 21]. In total, blood samples from 311 subjects were included in our study. The distribution of control, MCI, and dementia subjects are shown in Table 1. The study subjects consisted of 72 dementia patients (average age 75.1 ± 0.68, 17 males, 55 females), 89 subjects with MCI (average age 73.72 ± 0.52, 36 males, 53 females), and 150 unrelated healthy control subjects (average age 72.34 ± 0.37, 65 males, 85 females). Table 1 summarizes demographic and clinical measures for all covariates tested here, including diagnosis (normal, MCI, dementia), the mini-mental state exam (MMSE), and global clinical dementia rating (CDR). CDR scores are 0 for normal, 0.5 for questionable dementia, 1 for mild dementia, 2 and 3 for moderate to severe dementia[22]. All participants provided written informed consent and no formal psychological tests or assessments were used to determine whether participants were able to provide written informed consent. The consent procedure and data acquisition procedure of this study were approved by the Institutional Review Board (IRB) of the Korea Centers for Disease Control and Prevention (KCDC) with approval numbers (2016-02-22-P-A, 2017-05-05-P-A). All experiments were performed in accordance with relevant guidelines and regulations.

Table 1

Baseline characteristics of the study population.

Features	Control	MCI	Dementia	p-value
N (Male/Female)	150(65/85)	89(36/53)	72(17/55)
Age (yr)	72.34±0.37	73.72±0.52	75.1±0.68	<0.001
Education	9.28±0.39	6.02±0.51	3.30±0.51	< 0.001
MMSE	27.33±0.17	24.65±0.34	15.92±0.68	<0.001
CDR	0.037±0.01	0.26±0.02	1.11±0.08	<0.001
sNotch1 (ng/mL)	2.81±0.17	2.23±0.07 a	2.1±0.07 b	0.015

Values are mean ± SEM

acompared with control; p < 0.01,

bcompared with control; p < 0.001

Key: MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; CDR, clinical dementia rating; SEM, standard error of the mean.

Cell cultures

Human umbilical vein endothelial cells (HUVECs) (Lonza, Walkersville, MD, USA) were cultured on 0.2% gelatin-coated wells in Endothelial Growth Medium-2 (EGM-2) media (Lonza) with 2% fetal bovine serum (FBS) at 37°C in a humidified incubator with 5% CO2, as previously described passages[23] 6–9 were used for experimentation. Primary human brain microvascular endothelial cells (HBMECs) were from Cell systems (Kirkland, WA, USA) and maintained in CSC complete medium with 10% serum and CultureBoost (Cell systems). All primary HBMECs cultures were used between passage 4 and 9. Human iPSC-derived neural progenitor stem cells were obtained from Axol Bioscience (Little Chesterford, UK) and were differentiated to cerebral cortical neurons in approximately 7 days following the recommended manufacturer’s protocol.

Antibodies and Reagents

The following primary antibodies were used: anti-Notch1 intracellular domain (NICD) (Cell Signaling Technology, MA, USA), anti-Notch1 extracellular domain (NEXT) (Thermo Fisher Scientific, MA, USA), anti-Hey-1 (GeneTex, CA, USA), anti-Actin (TransGen, Beijing, China). Synthetic amyloid-beta peptides 1–40 (Aβ1–40) were purchased from Invitrogen (Invitrogen, CA, USA) and dissolved in hexafluoreisopropanol (HFIP) (Sigma, MO, USA) for 2 h at room temperature, and lyophilized peptide was dissolved in dimethylsulfoxide (DMSO).

ELISA measurements

The cell-free plasma samples were stored in aliquoted and stored at -80 ºC until assayed collectively by an investigator who was blinded to the patient assignment. Enzyme-linked immunosorbent assay (ELISA) was used to measure the human Notch1 level according to the manufacturer’s instructions (USCN, Wuhan, China).

Western blotting

Cells and mouse brains were collected and homogenized in radio-immunoprecipitation assay buffer (RIPA buffer; 20 mM Tris, pH 7.4, 150 mM NaCl, 1 mM Na3VO4, 10 mM NaF, 1 mM EDTA, 1 mM EGTA, 0.2 mM PMSF, 1% Triton X-100, 0.1% SDS, 0.5% deoxycholate), protein concentration were determined using a Bradford protein assay following the manufacturer’s instruction. Bolt 4~12% Bis-Tris gradient gels were used for SDS-PAGE in MES SDS buffer (Life technology, NY, USA). The primary antibodies were diluted in PBS with 5% nonfat dry milk and 0.1% Tween 20 as follows: anti-NICD (1:1,000), anti- NEXT (1:1,000), anti- Hey-1 (1:1,000), and anti-Actin (1:10,000).

Quantitative real-time polymerase chain reaction (qRT-PCR)

qRT-PCR was performed using SYBR Green PCR core reagent, in a two-step RT-PCR protocol according to the manufacturer’s instructions (Applied Biosystems, Warrington, UK). Initial denaturation at 95 ºC for 10 min was followed by 40 amplification cycles of 95 ºC for 15 seconds and 58 ºC for 1 min. The primer sequences are as follows; NOTCH1 sense 5’- GAGGCGTGGCAGACTATGC -3’ and antisense 5’- CTTGTACTCCGTCAGCGTGA -3’; ADAM10 sense 5’- TGGCCAACCTATTTGTGGAA -3’ and antisense 5’- CCTCTGGTTGATTTGCATCG -3’; GAPDH sense 5’- CAGCCTCAAGATCATCAGCA -3’ and antisense 5’- TGTGGTCATGAGTCCTTCCA -3’. GAPDH was used as an internal normalizer. PCR reactions were performed using ABI Prism 7900 SDS (Applied Biosystems, Warrington, UK). Data were analyzed using ΔΔCt method. ΔCt is the difference in the Ct values of the test gene (in each sample assayed) and GAPDH gene, while ΔΔCt represented the difference between the paired samples. All the experiments were performed in triplicates.

Statistical analysis

Data are presented as the mean ± standard error of the mean (SEM). To analyze demographic and plasma levels of target proteins between dementia, MCI, and control groups, Kruskal-Wallis test was performed followed by Mann-Whitney U-tests. Correlation between factors was analyzed by Spearman’s method. Statistical analyses were performed using SPSS 12.0 (IBM, NY, USA). Values of p < 0.05 were considered statistically significant. Demographic and clinical differences between control, MCI and dementia group were tested using the Pearson's Chi-squared test, Fisher’s exact test and Kruskal-Wallis test.

Results

Correlations of sNotch1 levels in dementia patients and healthy subjects

Participant’s characteristics are depicted in Table 1. Patients with dementia were older compared to control subjects. The mean age of the control, dementia subjects, and subjects with mild cognitive impairment (MCI) were 72.34 ± 0.37 years, 75.1 ± 0.68 years, and 73.72 ± 0.52 years respectively. The percentage of women amongst control, dementia, and MCI subjects were 57%, 76%, and 60% respectively. Patients with dementia were less educated compared to the control subjects. The overall MMSE scores were lower in patients with dementia, while it was in the normal range in MCI and healthy control subjects.

For analyzing sNotch1 concentration in the plasma, we established a commercial sensitive ELISA method (Fig 1A). Our results showed that the sNotch1 concentration in the plasma was different between the three groups (p < 0.05; Kruskal-Wallis test). It was lower in subjects with MCI (2.23 ± 0.07 ng/mL) and dementia (2.1 ± 0.07 ng/mL), as compared to the control subjects (2.81 ± 0.17 ng/mL) (p = 0.015; Mann-Whitney U-tests) (Table 1). Quantitatively, sNotch1 levels in the plasma samples of dementia patients were 25.27% lower as compared to control subjects (Fig 1B).

Fig 1

Comparison of the plasma levels of sNotch1.

(a) Standard curve of the human Notch1 ELISA kit. (b) Plasma sNotch1 concentration was measured by ELISA. The differences in the relative amounts of sNotch1 were compared between control, MCI, and AD by means of Mann-Whitney’s U-test within different groups.

Table 2 indicates that there is a positive correlation between the plasma level of sNotch1 and the results of the MMSE assessments in the entire study population. In contrast, the CDR assessment is negatively correlated with the plasma level of sNotch1. No correlation is observed between sNotch1 levels and the age or the gender of the subjects in any of the studied groups; however, it was associated with the participant’s level of education.

Table 2

Correlation between plasma Notch1 and clinical rating scales.

Features	Rho	p Value
Ages	0.016	0.781
Education	0.140	0.013
MMSE	0.134	0.018
CDR	-0.117	0.038

Spearman rank correlation coefficient test was used for assessment of correlations.

Bold values are p < 0.05.

Key: MMSE, Mini-Mental State Examination; CDR, clinical dementia rating.

Notch1 is increased in endothelial cells by Aβ in vitro

To explore the molecular mechanisms regulating sNotch1 level in AD, we investigated sNotch1 levels in endothelial cells (ECs). We examined whether Aβ could modulate sNotch1 levels, which could possibly explain its altered expression in AD patients. ECs were treated with Aβ1–40 peptides for 8 h or 24 h, and relative mRNA expression of target genes was measured by quantitative real-time PCR. Notch1 mRNA level was significantly increased after Aβ treatment for 8 h in human umbilical vein endothelial cells (HUVECs) (Fig 2A) as well as in human brain microvascular endothelial cells (HBMECs) (Fig 3A). Further, we examined the Notch1 protein level in ECs. After HUVECs were treated with 10 μM or 20 μM Aβ1–40 peptides for 24 h, NICD and Hey1 protein levels were significantly increased (Fig 2B). Consistently, treatment with 5 μM Aβ1–40 peptides for 24 h significantly increased the Notch1 and Hey1 protein levels in HBMECs (Fig 3B). These findings suggest that Aβ increases Notch1 mRNA and protein expressions in ECs.

Fig 2

Modulation of Notch1 expression in HUVECs by amyloid beta (Aβ).

(a) HUVECs were treated with 10 μM or 20 μM Aβ1–40 peptides for 8 h. Real-time PCR results showing relative mRNA expression levels of Notch1 (n = 3). (b) HUVECs were treated with 10 μM or 20 μM Aβ1–40 peptides for 24 h. Notch1 intracellular domain (NICD) and Hey1 protein levels were detected in HUVECs lysate. Treatment with 10 μM Aβ1–40 peptides for 24 h significantly increased the Notch1 and Hey1 protein levels (n = 3). Actin was used as a loading control. Secreted soluble Notch1 levels were analyzed by western blotting. Conditioned media were harvested from HUVECs treated with 10 μM or 20 μM Aβ1–40 for 24 h. Notch1 extracellular domain (NEXT) protein was not detectable in HUVECs culture media.

Fig 3

Modulation of Notch1 expression in HBMECs by amyloid beta (Aβ).

(a) HBMECs were treated with 5 μM or 10 μM Aβ1–40 peptides for 8 h. Real-time PCR results showing relative mRNA expression levels of Notch1 (n = 3). (b) HBMECs were treated with 5 μM or 10 μM Aβ1–40 peptides for 24 h. Notch1 intracellular domain (NICD) and Hey1 protein levels were detected in HBMECs lysate. Treatment with Aβ1–40 peptides for 24 h significantly increased the Notch1 and Hey1 protein levels (n = 3). Actin was used as a loading control. Secreted soluble Notch1 levels were analyzed by western blotting. Conditioned media were harvested from HBMECs treated with 5 μM or 10 μM Aβ1–40 for 24 h. After treatment with 5 μM Aβ peptides, Notch1 extracellular domain (NEXT) protein level was significantly increased in HBMECs culture media.

Modulation of sNotch1 level by Aβ in vitro

We next investigated the soluble Notch1 (sNotch1) protein levels in cell culture media using a specific antibody against C-terminus of full-length Notch1, which could detect the secreted sNotch1 extracellular domain (NEXT). After treatment with 5 μM Aβ for 24 h, secreted NEXT protein levels were significantly increased in HBMECs culture media (Fig 3C) but was undetectable in HUVECs culture media (Fig 2C). These findings suggest that Aβ may increase the N-terminal cleavage of full-length Notch1 protein into secreted forms in ECs culture media.

ADAM10 is increased in endothelial cells by A β in vitro

To understand how sNotch1 is increased in culture media, we investigated ADAM10 expression levels in endothelial cells (ECs). ECs were treated with Aβ1–40 peptides for 8 h or 24 h, and relative mRNA expression of target genes was measured by quantitative real-time PCR. After treatment with 10 μM Aβ1–40 peptides, ADAM10 mRNA level was significantly increased in HUVECs (Fig 4A, * p < 0.05) and HBMECs (Fig 4B, ** p < 0.01). Increased ADMA10 mRNA expression might affect to the cleavage of Notch1 extracellular domain under the Aβ-treated condition in ECs. So, it could be explain that secreted sNotch1 extracellular domain (NEXT) is increased in HBMECs culture media.

Fig 4

ADAM10 mRNA expression in ECs by amyloid beta (Aβ).

HUVECs (a) and HBMECs (b) were treated with 10 μM Aβ1–40 peptides for 8 h or 24 h. Real-time PCR results showing relative mRNA expression levels of ADAM10 (n = 3). Treatment with 10 μM Aβ1–40 peptides significantly increased the ADAM10 mRNA expression levels (* p < 0.05 and ** p < 0.001, respectively).

Aβ increases Notch1 expression in human iPSC-derived neuronal cells

We next examined Notch1 mRNA expression in human iPSC-derived neuronal cells by quantitative real-time PCR. Notch1 mRNA levels were measured in human iPSC-derived neuronal cells from an AD patient and a healthy control subject (n = 3). Human iPSC cells were differentiated into neurons using commercial neuronal differentiation media. As we expected, Notch1 mRNA expression was significantly increased in human iPSC-derived neuronal cells from an AD patient compared to a healthy control subject with p < 0.05 (Fig 5A). We also measured the Hey1 and Hes5 mRNA levels in iPSC-derived AD neurons and healthy neurons (n = 3, respectively). Hey1 and Hes5 mRNA expression were significantly increased in human iPSC-derived neuronal cells from an AD patient with both p < 0.01 (Fig 5B and 5C). These results suggest that Notch1 levels are increased in patients with AD.

Fig 5

Notch1 mRNA expression in human iPSC-derived neuronal cells.

(a) Relative Notch1 mRNA expression levels were measured in human iPSC-derived neuronal cells from an AD patient and a healthy control subject (n = 3). Human iPSC cells were differentiated to neurons by treating with neuronal differentiation media. Notch1 mRNA expression was significantly increased in human iPSC-derived neuronal cells from an AD patient (* p < 0.05). (b-c) Relative Hey1 and Hes5 mRNA expression levels were measured (n = 3, respectively) and significantly increased in human iPSC-derived neuronal cells from an AD patient (both ** p < 0.01).

Discussion

Alzheimer’s disease (AD) and vascular dementia (VAD) are the two main types of dementia affecting approximately 70% and 15%, respectively, of all demented patients[24]. Recent neuropathological studies have demonstrated that patients with AD have concomitant cerebrovascular pathology[25]. Notch signaling is involved in a number of cellular processes such as cell-cell interactions, crosstalk with neighboring cells, vasculogenesis, angiogenesis, permeability, and survival. Although Notch signaling cascade responds to microenvironmental conditions through cell-cell interactions, several other stimuli including aging, shear stress, inflammation, hypoxia, and hyperglycemia are known to activate this pathway[4, 26–29].

In endothelial cells (ECs), Notch signaling has been reported to modulate angiogenesis through the repression of VEGFR2[30]. Angiogenesis and vascular dysfunction may be involved in neurodegeneration[31]. VEGF levels are increased in tissues obtained from the patients with AD[32] and VEGF/Notch signaling cascade may play an important role in the pathology of AD including BBB leakage. Notch1 is proteolytically cleaved by γ-secretase, releasing the NICD into the cytoplasm, which then translocates to the nucleus and regulates expressions of several genes including Hey1 and Hes5[33]. Previous studies have reported that Notch1 is upregulated in the brain of AD patients[34, 35]. Notch1 plays an important role in the maintenance of neuronal stem cells[36], regulating neurogenesis[37], and activating stem cells in response to injury for increased neurogenic demand[38]. Activation of Notch1 signaling induced by cerebral ischemia results in a protracted nuclear factor-κB (NF-κB)-driven microglia-mediated neuroinflammation and worsens ischemic brain damage and functional outcome[39]. Activated microglial cells are detected in peri-infarct areas in clinical stroke and though to orchestrate neuronal damages in the penumbra[10]. Recent studies raise the possibility of the links between the Notch signaling pathway and diverse pathological disorders including adaptive and innate immune responses, multiple sclerosis, inflammatory demyelinating disease, which is providing Notch as a novel prospective target for the treatment of neuroinflammation-related degenerative disorders.

Notch signaling is also important for normal adult brain function and is implicated in various neurological diseases. However, the role of Notch signaling in fine-tuning neurogenesis and neurodegenerative pathology is not fully understood. Studies showed a link between Notch and neurological disorders including Alagille syndrome, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) syndrome, mental retardation, and certain types of schizophrenia[40]. In addition, Notch1 is overexpressed in the neurogenic and non-neurogenic regions of the brain in sporadic Alzheimer’s disease and adults with Down syndrome[41]. Consistent with these findings, we found that Notch1 expression was increased in Aβ-treated ECs. These results indicate that the levels of Notch1 and sNotch1 might be associated with dysregulated proteostasis in neurodegenerative disorders such as AD. Mutations in Notch2 gene induces Down syndrome and Notch3 mutations lead to cardiovascular disorder CADASIL that causes stroke and vascular dementia with degenerative changes in the vascular smooth muscles. Several familial AD mutations are known to be associated with diminished Notch activity but the mechanisms remain elusive[38].

Recent studies showed that chronic hippocampal expression of NICD induces vascular thickening with the accumulation of amyloid beta (Aβ) which exacerbates spatial memory deficits in a rat model of early AD. In addition, chronic activation of Notch1 signaling causes impaired blood flow while reducing nutrient delivery and worsening brain function in a McGill-R-Thy1-APP transgenic (Tg) rat model of early AD. These results suggest that chronic activation of Notch1 may accelerate Aβ accumulation and spatial memory deficits in Tg rodent models of AD[42].

Notch signaling has a critical roles in arterial formation and maturation. Dll4 and Jagged1 are important Notch1 ligands and were shown to have opposing effects in developmental angiogenesis. But the role of Jagged1/Notch signaling remains incompletely understood[43]. Notch signaling is associated with several pathological conditions and recent study shows that Notch signaling foster macrophage maturation during ischemia causing inflammatory responses[44]. Further studies will be required to examine Jagged1 and Dll4 to understand the role of Notch signaling in AD.

In our previous study, we showed the plasma levels of soluble VEGFR2 (sVEGFR2) in association with AD-related cognitive decline[8] and overexpression of NICD decreased the VEGFR2 mRNA levels in HUVECs[8]. Since recent study has reported that Notch1 is increased in AD[12], we further determined the alteration of the plasma levels of Notch1 in AD with the population as described in detail previous[8, 16].

Here we investigated Notch1 expression in human AD patients. We found that NICD and secreted soluble NEXT protein levels are significantly increased in Aβ-treated ECs in vitro. Notch1 mRNA expression is also significantly increased in human iPSC-derived neuronal cells. These results might implicate an increase in the Notch1 deposition in the amyloid plaques within the brain tissue of AD patients. Although Notch1 expression was induced by Aβ in ECs, the plasma levels of sNotch1 were significantly reduced in patients with AD. Our study provides a possible explanation that increased full-length and truncated Notch1 proteins are localized at the amyloid plaques, thereby reducing the sNotch1 level in the plasma. Decrease in plasma sNotch1 level consequently leads to reduced full-length and truncated Notch1 protein in cerebrospinal fluid (CSF) of AD patients[12]. The present study demonstrates that the plasma level of Notch1 correlates with cognitive decline in patients with dementia. We found that plasma levels of Notch1 were significantly lower in patients with AD than in patients with MCI or healthy control subjects. Accumulation of Notch1 and colocalization with the amyloid-beta plaques in AD patient’s brain might explain the reduced levels of plasma sNotch1 in these patients. Further studies are required to understand the mechanism of decreased plasma sNotch1 levels in AD, which will be helpful in deciphering the role of Notch1 signaling in neuropathological conditions.

In conclusion, our results show that plasma sNotch1 levels are decreased in patients with AD. We suggest that alteration in sNotch1 level might be associated with those at risk for Alzheimer’s disease.

Original uncropped and unadjusted full blots of Fig 2B and 2C.

(PDF)

Click here for additional data file.

Original uncropped and unadjusted full blots of Fig 3B and 3C.

(PDF)

Click here for additional data file.

8 Aug 2019

PONE-D-19-18002

Altered expression of Notch1 in Alzheimer's disease

PLOS ONE

Dear Dr. Koh,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Sep 22 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Dong-Gyu Jo, Ph.D

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

1. Please describe in your methods section how capacity to provide consent was determined for the participants in this study. Please also state whether your ethics committee or IRB approved this consent procedure.

2. Our internal editors have looked over your manuscript and determined that it may be within the scope of our Early Diagnosis and Treatment of Alzheimer's Disease Call for Papers. This collection of papers is headed by a team of Guest Editors for PLOS ONE: Michael Weiner, Roberta Brinton, Jussi Tohka and Yona Levites. With this Collection we hope to bring together researchers working on a wide range of disciplines, from molecular and preclinical work, through to patient-centered studies, including clinical trials.   Additional information can be found on our announcement page: https://collections.plos.org/s/alzheimersdisease. If you would like your manuscript to be considered for this collection, please let us know in your cover letter and we will ensure that your paper is treated as if you were responding to this call. If you would prefer to remove your manuscript from collection consideration, please specify this in the cover letter.

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

4. Please amend your list of authors on the manuscript to ensure that each author is linked to an affiliation. Authors’ affiliations should reflect the institution where the work was done (if authors moved subsequently, you can also list the new affiliation stating “current affiliation:….” as necessary).

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: 1. Table1: They also should demonstrate the specificity of the antibody.

2. Table1: The bar plot would help to understand the variations of the data.

3. Figure 3: The authors described that mRNA levels of Notch1 are increased iPSC-derived AD neurons. Do you think it is Notch1 specific? The authors also should measure at least one more gene in these samples, hey-1 or hes-5.

4. Before resubmitting, I would recommend having the manuscript reviewed by a native English speaker.

5. The manuscript should format according to the jorunal instruction. some parts including reference part is not well formatted.

Reviewer #2: In this paper, the authors show that Notch1 signaling is modulated by pathological condition such as Alzheimer’s disease. The manuscript is well-written, but the current data is missing some points.

1. As mentioned by the authors, it is well known that Notch1 extra-cellular domain is cleaved by metalloprotease ADAM10. To understand how sNotch1 is increased in culture media need to confirm the ADAM 10 expression.

2. Since Notch1 ligands, Dll4 and Jag1, have opposite effects and is required to activate Notch1 signaling in endothelial cell differentiation in artery. Investigation of these protein will give more information about activation of Notch1.

3. Notch1 signaling is activated by not only development stage but also pathological condition such as ischemic stroke, neuronal death, and followed inflammatory responses. Please, cite and discuss those related previous findings which will be helpful to understand role of Notch1 signaling in neurodegenerative diseases.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

20 Sep 2019

Reviewer #1: I have incorporated all of your suggestions into my revision. Thank you.

Reviewer #2: I have incorporated all of your suggestions into my revision. Thank you.

Submitted filename: Response to Reviews_Revision_20190920.docx

Click here for additional data file.

25 Oct 2019

Altered expression of Notch1 in Alzheimer's disease

PONE-D-19-18002R1

Dear Dr. Koh,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Dong-Gyu Jo, Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

18 Nov 2019

PONE-D-19-18002R1

Altered expression of Notch1 in Alzheimer's disease

Dear Dr. Koh:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Dong-Gyu Jo

Academic Editor

PLOS ONE